'Advise restraint on prescribing acid reflux pills'

'Advise restraint on prescribing acid reflux pills'

Commonly used PPIs in India include Omeprazole, Lansoprazole, DEXlansoprazole, Pantoprazole, Esmoprezole, Rabeprazole.

Taking strong cognisance of the latest study claiming that common Proton Pump Inhibitors (PPIs) like pantoprazole and rabeprazole may double the risk of developing stomach cancer, Indian doctors on Wednesday advised the fraternity to be cautious while prescribing such pills to patients.

“We know that due to significant acid suppression, PPIs can exacerbate atrophic gastritis which may lead to gastric cancer,” Sudeep Khanna, senior consultant (Gastroenterology, Hepatology and Therapeutic Endoscopy) at Indraprastha Apollo Hospitals in New Delhi, told IANS.

“Yes definitely, doctors should take a second call before prescribing PPIs to patients,” Khanna added.

Commonly used PPIs in India include Omeprazole, Lansoprazole, DEXlansoprazole, Pantoprazole, Esmoprezole, Rabeprazole.

Because “regular usage can double the risk of stomach cancer… doctors should maintain caution while prescribing the PPIs,” noted Vinay Samuel Gaikwad, senior consultant and head of department Oncology, at Paras Hospitals in Gurugram. (IANS)